Personal CFO Solutions LLC Purchases New Shares in ResMed Inc. (NYSE:RMD)

Personal CFO Solutions LLC purchased a new stake in shares of ResMed Inc. (NYSE:RMD) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,291 shares of the medical equipment provider’s stock, valued at approximately $295,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Amundi boosted its position in shares of ResMed by 4.2% in the 4th quarter. Amundi now owns 590,212 shares of the medical equipment provider’s stock worth $139,386,000 after purchasing an additional 23,775 shares during the last quarter. River Global Investors LLP bought a new position in shares of ResMed in the 4th quarter worth $9,575,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of ResMed in the 4th quarter worth $267,000. Andra AP fonden bought a new position in shares of ResMed in the 4th quarter worth $8,850,000. Finally, Callan Family Office LLC bought a new position in shares of ResMed in the 4th quarter worth $1,550,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ResMed

In related news, insider Kaushik Ghoshal sold 9,113 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the completion of the sale, the insider now directly owns 9,725 shares in the company, valued at approximately $2,289,265. The trade was a 48.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the sale, the chief executive officer now owns 455,472 shares of the company’s stock, valued at approximately $107,842,105.44. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,186 shares of company stock worth $4,996,646. Company insiders own 0.71% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Stifel Nicolaus dropped their price objective on ResMed from $250.00 to $240.00 and set a “hold” rating on the stock in a research note on Wednesday, March 5th. StockNews.com downgraded ResMed from a “buy” rating to a “hold” rating in a research note on Friday. UBS Group raised ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Friday, January 31st. Finally, KeyCorp lifted their price target on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $243.82.

ResMed Trading Up 2.1 %

Shares of NYSE:RMD opened at $237.42 on Tuesday. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05. The stock has a market cap of $34.87 billion, a PE ratio of 28.03, a P/E/G ratio of 1.53 and a beta of 0.74. The business has a 50 day moving average of $236.86 and a 200-day moving average of $240.13. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Thursday, February 13th. ResMed’s dividend payout ratio (DPR) is currently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.